64 completed. 64 Phase 3, 24 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Completed 64 |
| Phase 2 | 24 | Completed 24 |
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HEALEY ALS Platform Trial - Regimen G DNL343 DNL343, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 249 | 2023-05-24 | 2026-01-28 |
| HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262 ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 310 | 2023-03-23 | 2025-11-14 |
| Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 27 | 2023-01-12 | 2026-01-13 |
| Extension Study Evaluating The Safety And Tolerability of AMX0035 AMX0035 - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 352 | 2022-12-29 | 2025-01-13 |
| Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Apitegromab, Placebo - Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 | Phase 3 | Completed | Scholar Rock, Inc. | 188 | 2022-04-14 | 2026-01-22 |
| HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose SLS-005, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 161 | 2022-02-21 | 2025-05-14 |
| Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) OAV101, Sham control - Type 2 Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 126 | 2022-02-01 | 2026-01-13 |
| Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis FAB122, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Ferrer Internacional S.A. | 313 | 2021-10-18 | 2025-03-18 |
| Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 24 | 2021-09-08 | 2024-10-09 |
| A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) Nusinersen - Muscular Atrophy, Spinal | Phase 3 | Completed | Biogen | 115 | 2021-04-19 | 2026-08-11 |
| Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS Lenzumestrocel, Riluzole, Placebo Comparator - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Corestemchemon, Inc. | 123 | 2021-02-24 | 2026-04-30 |
| HEALEY ALS Platform Trial - Regimen D Pridopidine Pridopidine, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 163 | 2020-12-18 | 2023-08-23 |
| A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) AMX0035 - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 28 | 2020-11-22 | 2023-04-07 |
| Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) MT-1186 - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 124 | 2020-10-29 | 2026-07-20 |
| HEALEY ALS Platform Trial - Regimen C CNM-Au8 CNM-Au8, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 161 | 2020-07-30 | 2023-07-25 |
| HEALEY ALS Platform Trial - Regimen A Zilucoplan Zilucoplan, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 162 | 2020-07-29 | 2023-07-25 |
| HEALEY ALS Platform Trial - Regimen B Verdiperstat Matching Placebo, Verdiperstat - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | Merit E. Cudkowicz, MD | 167 | 2020-07-28 | 2023-06-12 |
| Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Nusinersen - Muscular Atrophy, Spinal | Phase 3 | Completed | Biogen | 145 | 2020-03-26 | 2025-06-05 |
| Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Onasemnogene Abeparvovec-xioi - Spinal Muscular Atrophy Type I | Phase 3 | Completed | Novartis Gene Therapies | 2 | 2019-05-31 | 2026-01-26 |
| Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis Deferiprone, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University Hospital, Lille | 372 | 2019-01-30 | 2025-12-05 |
Showing 20 of 64. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (49) · Muscular Atrophy, Spinal (13) · Muscular Atrophy (6) · Bulbo-Spinal Atrophy, X-Linked (3) · Muscular Diseases (3) · Spinal Muscular Atrophies of Childhood (3) · Multiple Sclerosis (2) · Neuromuscular Diseases (2) · Sialorrhea (2) · Anorexia (1) · Atrophy (1) · Cachexia (1) · Depression (1) · Depressive Disorder, Major (1)
Nervous System Diseases (64) · Neurodegenerative Diseases (64) · Central Nervous System Diseases (63) · Spinal Cord Diseases (63) · Neuromuscular Diseases (62) · Metabolic Diseases (49) · Nutritional and Metabolic Diseases (49) · Proteostasis Deficiencies (49) · TDP-43 Proteinopathies (49) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Neurologic Manifestations (8) · Neuromuscular Manifestations (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)
Edaravone (5) · Zolgensma (5) · Riluzole (4) · nusinersen (4) · mecobalamin (3) · CK-2017357 (2) · arimoclomol (2) · dextromethorphan - quinidine combination (2) · olesoxime (2) · rimabotulinumtoxinB (2) · sodium phenylbutyrate and taurursodiol (2) · 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (1) · 4-Aminopyridine (1) · Administration, Intravenous (1) · Ceftriaxone (1)
Merit E. Cudkowicz, MD (7) · Biogen (5) · Shionogi (5) · Eisai Co., Ltd. (3) · Novartis Gene Therapies (3) · Novartis Pharmaceuticals (3) · Amylyx Pharmaceuticals Inc. (2) · Avanir Pharmaceuticals (2) · Cytokinetics (2) · Hoffmann-La Roche (2) · AB Science (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Inc (1) · Brainstorm-Cell Therapeutics (1) · Catholic University of the Sacred Heart (1)
United States (37) · France (19) · Italy (18) · Germany (17) · Spain (17) · Canada (16) · Belgium (15) · United Kingdom (15) · Japan (14) · Netherlands (10) · Australia (7) · Sweden (7) · Taiwan (7) · Ireland (6) · Poland (6)
Merit Cudkowicz, MD (5) · Kazunori Saeki (2) · Merit Cudkowicz (2) · Merit Cudkowicz, MD, MSc (2) · Adrian Hepner, M.D. (1) · Anthony J. Windebank, MD (1) · Carlayne E Jackson, MD (1) · Charles B Simpson, MD (1) · Charles M Wiener, MD (1) · Christen L Shoesmith, MD, FRCPC (1) · Claudia A. Chiriboga, MD, MPH (1)
PMID 34383289, PMID 25982504, PMID 14718694, PMID 15505150, PMID 17980667, PMID 19029516, PMID 19682544, PMID 19743466, PMID 20839238, PMID 21887710, PMID 23613806, PMID 24067398, PMID 25286015, PMID 25297012, PMID 28522181, PMID 28864675, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 29367439, PMID 29402141, PMID 29443664, PMID 30554828, PMID 30578206, PMID 30636701, PMID 30814647, PMID 31420846, PMID 31930364, PMID 32640130, PMID 33743238, PMID 34433481, PMID 34457038, PMID 34536404, PMID 35397772, PMID 35532908, PMID 35567345, PMID 35585556, PMID 35715566, PMID 35715567, PMID 36129998, PMID 37311173, PMID 37525592, PMID 37975798, PMID 38705943, PMID 38782015, PMID 39513379, PMID 39804575, PMID 40067754
2014 (2), 2015 (2), 2017 (2), 2016 (1), 2019 (1), 2023 (1), R01NS042759 (1), U01NS049640 (1)